Cabotegravir sodium

THURSDAY, Aug. 8, 2024 -- Long-acting injectable cabotegravir (CAB-LA) appears to be well tolerated in pregnant women, according to a study presented at AIDS 2024, the 25th International AIDS Conference, held from July 22 to 26 in Munich. Sinead Delany-Moretlwe, M.B.B.Ch., Ph.D., from the University of the Witwatersrand in South Africa, and colleagues reported on maternal safety and pregnancy outcomes among 2,472 participants in the HPTN 084 open-label extension. Pregnancies were categorized by exposure to CAB-LA injections during pregnancy, CAB-LA injections before pregnancy only, and no CAB-LA exposure (tenofovir disoproxil fumarate/emtricitabine [TDF/FTC] group). The researchers identified 351 confirmed incident pregnancies in 334 participants during 3,118 person-years (incidence, 11.3/100 person-years). The median time from last injection to pregnancy detection was eight and 13 weeks among participants with CAB-LA use during or prior to pregnancy, respectively. Participants with CAB-LA use during pregnancy received a median of four injections. No maternal deaths were reported. The incidence of pregnancy-related maternal adverse events was 43.7, 52.9, and 40.0 per 100 person-years among those using CAB-LA during pregnancy, those using prior to pregnancy, or those without CAB-LA exposure, respectively. Across groups, poor pregnancy outcome rates were similar, with negative outcomes reported in 28, 35, and 26 percent of pregnancies with CAB-LA use during pregnancy, prior to pregnancy, or without CAB-LA exposure, respectively. There was one major congenital anomaly (in the group receiving CAB-LA during pregnancy). "We hope that these findings can fill an important knowledge gap that can help increase access to this highly effective HIV preexposure prophylaxis option among cisgender women before, during, and after pregnancy," Delany-Moretlwe said in statement. Press Release More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

MONDAY, July 29, 2024 -- In a research letter published online July 24 in the New England Journal of Medicine , the authors describe long-acting early viral inhibition (LEVI) among patients with acute HIV infection in the context of long-acting injectable cabotegravir (CAB-LA) preexposure prophylaxis (PrEP). The research was published to coincide with the 25th International AIDS Conference, held from July 22 to 26 in Munich. Noting that in the HIV Prevention Trials Network (HPTN) 083 and 084 trials, altered presentation of acute HIV infection in the context of CAB-LA PrEP, LEVI was observed, Raphael J. Landovitz, M.D., from the University of California in Los Angeles, and colleagues examined presentations of HIV infection involving LEVI and classic HIV infection. The authors note that cases involving LEVI were characterized by low or undetectable HIV viral load and reduced or delayed antibody production, and were usually clinically silent. HIV antigens, antibodies, RNA, and DNA levels were often near the level of detection of available assays, which may revert from reactive, indeterminate, or positive to nonreactive or negative, challenging confirmation of HIV. Forty-one HIV infections were identified among 3,446 participants who had been randomized to receive CAB-LA in trials HPTN 083 and 084; detection of an infection was delayed in 17 (41 percent) when an HIV rapid test and a HIV antigen and antibody test were used for screening. "When interpreting HIV test results in persons who are receiving CAB-LA PrEP, providers should recognize that a prolonged period of observation with frequent retesting may be needed before infection can be confirmed or ruled out," the authors write. Several authors disclosed ties to biopharmaceutical companies, including ViiV Healthcare and Gilead Sciences, which donated trial medications and matching placebos. ViiV Healthcare provided additional funding.